Axsome Therapeutics Inc
AXSM
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.95B
Close$
$23.38
89.1% downside
Current Fair Value
89.1% downsideOvervalued by 89.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.95 Billion |
|---|---|
| Enterprise Value | $10.85 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.68 |
| Beta | 0.6 |
| Outstanding Shares | 51,198,349 |
Return
| Return on Equity | -230.05% |
|---|---|
| Return on Assets | -25.17% |
| Return on Invested Capital | -57.44% |
Valuation & Multiples
| P/E Ratio | -57.03 |
|---|---|
| PEG | -818.96 |
| Price to Sales | 14.25 |
| Price to Book Ratio | 213.68 |
| Enterprise Value to Revenue | 13.97 |
| Enterprise Value to EBIT | -62.74 |
| Enterprise Value to Net Income | -57 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 2.63 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.89
Average shareholder expectationRevenue Estimate
$221.11 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.42
Average shareholder expectationRevenue Estimate
$259.21 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.2500▲ 31.10% |
|---|---|
| Total Calls | 6,000▼ 99.15% |
| Total Puts | 7,500▼ 98.87% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 14.19%▼ 62.02% |
|---|---|
| Total Invested | $1.77B▼ 72.35% |
| Investors Holding | 198▼ 232.00% |
ESG Score
No data
About Axsome Therapeutics Inc
CEO: Herriot Tabuteau Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory tre...